Pharmalittle: We're reading about an FDA panel and peptides, a Merck license for an HIV pill, and more

An advisory panel to the FDA has recommended that compounding pharmacies be permitted to produce specific peptides including BPC-157, KPV, TB-500, and MOTS-c. While these drugs have gained popularity among certain users, FDA staff expressed concerns regarding their safety and efficacy. This non-binding recommendation highlights an ongoing tension between the agency and advisors appointed under the current administration.

In separate developments, patients who rely on the Sanofi Lantus Solostar insulin pen are reporting significant difficulty finding their medication. Sanofi states that increased market demand is responsible for the recent supply issues. While the situation remains challenging for those managing diabetes, it is not currently classified as an official shortage by the FDA.

Finally, Merck has announced new voluntary licensing agreements aimed at expanding access to its experimental HIV prevention pill. These deals are specifically structured to reach populations in lower-income countries. The move represents a notable shift in how large manufacturers are managing patents for critical treatments in international markets.